Literature DB >> 29956477

Banff Lung Report: Current knowledge and future research perspectives for diagnosis and treatment of pulmonary antibody-mediated rejection (AMR).

A Roux1,2,3, D J Levine4, A Zeevi5, R Hachem6, K Halloran7, P F Halloran8, L Gibault9, J L Taupin10, D A H Neil11, A Loupy2, B A Adam12, M Mengel12, D M Hwang13, F Calabrese14, G Berry15, E N Pavlisko16.   

Abstract

The Lung session of the 2017 14th Banff Foundation for Allograft Pathology Conference, Barcelona focused on the multiple aspects of antibody-mediated rejection (AMR) in lung transplantation. Multidimensional approaches for AMR diagnosis, including classification, histological and immunohistochemical analysis, and donor- specific antibody (DSA) characterization with their current strengths and limitations were reviewed in view of recent research. The group also discussed the role of tissue gene expression analysis in the context of unmet needs in lung transplantation. The current best practice for monitoring of AMR and the therapeutic approach are summarized and highlighted in this report. The working group reached consensus of the major gaps in current knowledge and focused on the unanswered questions regarding pulmonary AMR. An important outcome of the meeting was agreement on the need for future collaborative research projects to address these gaps in the field of lung transplantation.
© 2018 The American Society of Transplantation and the American Society of Transplant Surgeons.

Entities:  

Keywords:  alloantibody; classification systems: Banff classification; clinical research/practice; histocompatibility; lung (allograft) function/dysfunction; lung transplantation/pulmonology; microarray/gene array; pathology/histopathology; rejection: antibody-mediated (ABMR)

Mesh:

Substances:

Year:  2018        PMID: 29956477     DOI: 10.1111/ajt.14990

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  15 in total

1.  Association between Allosensitization and Waiting List Outcomes among Adult Lung Transplant Candidates in the United States.

Authors:  Laneshia K Tague; Chad A Witt; Derek E Byers; Roger D Yusen; Patrick R Aguilar; Hrishikesh S Kulkarni; Karen Bennett Bain; Keith A Fester; Varun Puri; Daniel Kreisel; Thalachallour Mohanakumar; Elbert P Trulock; Ramsey R Hachem
Journal:  Ann Am Thorac Soc       Date:  2019-07

Review 2.  Clinical relevance of lung-restricted antibodies in lung transplantation.

Authors:  Mahzad Akbarpour; Qiang Wu; Xianpeng Liu; Haiying Sun; Emilia Lecuona; Rade Tomic; Sangeeta Bhorade; Thalachallour Mohanakumar; Ankit Bharat
Journal:  Hum Immunol       Date:  2019-05-08       Impact factor: 2.850

Review 3.  Immunosuppression in Lung Transplantation.

Authors:  Joelle Nelson; Elisabeth Kincaide; Jamie Schulte; Reed Hall; Deborah Jo Levine
Journal:  Handb Exp Pharmacol       Date:  2022

4.  Validation of a Simple, Rapid, and Cost-Effective Method for Acute Rejection Monitoring in Lung Transplant Recipients.

Authors:  Monica Sorbini; Gabriele Togliatto; Fiorenza Mioli; Erika Simonato; Matteo Marro; Margherita Cappuccio; Francesca Arruga; Cristiana Caorsi; Morteza Mansouri; Paola Magistroni; Alessandro Gambella; Luisa Delsedime; Mauro Giulio Papotti; Paolo Solidoro; Carlo Albera; Massimo Boffini; Mauro Rinaldi; Antonio Amoroso; Tiziana Vaisitti; Silvia Deaglio
Journal:  Transpl Int       Date:  2022-06-09       Impact factor: 3.842

5.  Donor-derived cell-free DNA accurately detects acute rejection in lung transplant patients, a multicenter cohort study.

Authors:  Moon Kyoo Jang; Ilker Tunc; Gerald J Berry; Charles Marboe; Hyesik Kong; Michael B Keller; Pali D Shah; Irina Timofte; Anne W Brown; Ileana L Ponor; Cedric Mutebi; Mary C Philogene; Kai Yu; Aldo Iacono; Jonathan B Orens; Steven D Nathan; Sean Agbor-Enoh
Journal:  J Heart Lung Transplant       Date:  2021-04-24       Impact factor: 13.569

6.  FCGR3A and FCGR2A Genotypes Differentially Impact Allograft Rejection and Patients' Survival After Lung Transplant.

Authors:  Pascale Paul; Pascal Pedini; Luc Lyonnet; Julie Di Cristofaro; Anderson Loundou; Mathieu Pelardy; Agnes Basire; Françoise Dignat-George; Jacques Chiaroni; Pascal Thomas; Martine Reynaud-Gaubert; Christophe Picard
Journal:  Front Immunol       Date:  2019-06-12       Impact factor: 7.561

7.  Development and Optimization of an ELISA to Quantitate C3(H 2 O) as a Marker of Human Disease.

Authors:  Michelle Elvington; M Kathryn Liszewski; Alexis R Liszewski; Hrishikesh S Kulkarni; Ramsey R Hachem; Thalachallour Mohanakumar; Alfred H J Kim; John P Atkinson
Journal:  Front Immunol       Date:  2019-04-04       Impact factor: 7.561

Review 8.  Antibody-mediated rejection after lung transplantation.

Authors:  Amit I Bery; Ramsey R Hachem
Journal:  Ann Transl Med       Date:  2020-03

9.  Assessment of Carfilzomib Treatment Response in Lung Transplant Recipients With Antibody-mediated Rejection.

Authors:  Christine Pham; Brett J Pierce; Duc T Nguyen; Edward A Graviss; Howard J Huang
Journal:  Transplant Direct       Date:  2021-03-16

Review 10.  HLA Desensitization in Solid Organ Transplantation: Anti-CD38 to Across the Immunological Barriers.

Authors:  Nizar Joher; Marie Matignon; Philippe Grimbert
Journal:  Front Immunol       Date:  2021-05-20       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.